Flex Pharma is dedicated to creating innovative, novel treatments for neuromuscular disorders. Its programs have demonstrated initial human efficacy related to muscle cramping in healthy volunteers. The company plans to initiate efficacy studies in patients with neuromuscular disorders in the first half of 2015. Flex Pharma was founded by Rod MacKinnon, M.D. (2003 Nobel Laureate) and Bruce Bean, Ph.D., along with Chairman and CEO Christoph Westphal, M.D., Ph.D. The company raised $40 million in private funding and will use the proceeds to further advance its science and clinical candidates. It is backed by a mix of venture capital, crossover funds and strategic investors including Longwood Fund, Bessemer Venture Partners, EcoR1 Capital and Jennison Associates.

Total raised

$40M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2014